Efficacy of vaccines and disease activity linked to immunization are major concerns among people with multiple sclerosis (pwMS).
To assess antibody responses to seasonal influenza antigens and vaccine-associated neuroaxonal damage utilizing serum neurofilament light chain (sNfL) in pwMS receiving dimethyl fumarate (DMF).
In this prospective study, the 2020/2021 seasonal tetravalent influenza vaccine was administered to 20 pwMS treated with DMF and 15 healthy controls (HCs). The primary endpoints were responder rate of strain-specific antibody production (seroconversion or significant (4-fold) increase in influenza-antibody titers for ≥2/4 strains) at 30 days post-vaccination and changes in sNfL levels.
All patients treated with DMF fulfilled the responder criteria for immunization compared with 53% of the controls. However, higher proportions of HCs already had influenza-antibody titers ≥1:40 at baseline (53%
DMF-treated patients mount an adequate humoral immune response to influenza vaccines. Within the limits of the small cohort investigated, our data suggest that influenza immunization is not associated with clinical or subclinical disease reactivation.
Useful keywords (using NLM MeSH Indexing)
Dimethyl Fumarate/therapeutic use
Immunosuppressive Agents/therapeutic use
Multiple Sclerosis, Relapsing-Remitting*/drug therapy
Multiple Sclerosis, Relapsing-Remitting*/immunology
Find related publications in this database (Keywords)vaccination